465 related articles for article (PubMed ID: 37457288)
41. Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.
Pfeifer R; Al Rawashdeh W; Brauner J; Martinez-Osuna M; Lock D; Herbel C; Eckardt D; Assenmacher M; Bosio A; Hardt OT; Johnston ICD
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298141
[TBL] [Abstract][Full Text] [Related]
42. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
Lin YJ; Mashouf LA; Lim M
Front Immunol; 2022; 13():817296. PubMed ID: 35265074
[TBL] [Abstract][Full Text] [Related]
43. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
44. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
45. The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.
Johnson R; Sabnis N; McConathy WJ; Lacko AG
Pharmaceutics; 2013; 5(2):353-70. PubMed ID: 24244833
[TBL] [Abstract][Full Text] [Related]
46. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.
Li R; Cao L
Front Immunol; 2023; 14():1194020. PubMed ID: 37275874
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
[TBL] [Abstract][Full Text] [Related]
48. Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges.
Toulouie S; Johanning G; Shi Y
J Cancer; 2021; 12(4):1212-1219. PubMed ID: 33442419
[TBL] [Abstract][Full Text] [Related]
49. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
50. Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
Yoder R; Kimler BF; Staley JM; Schwensen K; Wang YY; Finke K; O'Dea A; Nye L; Elia M; Crane G; McKittrick R; Pluenneke R; Madhusudhana S; Beck L; Shrestha A; Corum L; Marsico M; Stecklein SR; Godwin AK; Khan QJ; Sharma P
NPJ Breast Cancer; 2022 Jul; 8(1):80. PubMed ID: 35817765
[TBL] [Abstract][Full Text] [Related]
51. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
52. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
53. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
54. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.
Yi H; Li Y; Tan Y; Fu S; Tang F; Deng X
Front Oncol; 2021; 11():648139. PubMed ID: 34094935
[TBL] [Abstract][Full Text] [Related]
55. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
56. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.
Ba H; Dai Z; Zhang Z; Zhang P; Yin B; Wang J; Li Z; Zhou X
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720496
[TBL] [Abstract][Full Text] [Related]
57. Mesothelin, a novel immunotherapy target for triple negative breast cancer.
Tchou J; Wang LC; Selven B; Zhang H; Conejo-Garcia J; Borghaei H; Kalos M; Vondeheide RH; Albelda SM; June CH; Zhang PJ
Breast Cancer Res Treat; 2012 Jun; 133(2):799-804. PubMed ID: 22418702
[TBL] [Abstract][Full Text] [Related]
58. Targeting triple negative breast cancer stem cells using nanocarriers.
Dasari N; Guntuku GS; Pindiprolu SKSS
Discov Nano; 2024 Mar; 19(1):41. PubMed ID: 38453756
[TBL] [Abstract][Full Text] [Related]
59. Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review.
Maqbool M; Bekele F; Fekadu G
Breast Cancer (Dove Med Press); 2022; 14():15-24. PubMed ID: 35046722
[TBL] [Abstract][Full Text] [Related]
60. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
